PDT Partners LLC Buys 74,957 Shares of Guardant Health, Inc. (NASDAQ:GH)

PDT Partners LLC boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 51.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 219,542 shares of the company’s stock after buying an additional 74,957 shares during the period. Guardant Health makes up about 0.4% of PDT Partners LLC’s investment portfolio, making the stock its 24th largest holding. PDT Partners LLC owned 0.18% of Guardant Health worth $5,036,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after buying an additional 796 shares during the last quarter. JNBA Financial Advisors purchased a new position in Guardant Health in the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health in the 3rd quarter worth approximately $34,000. Quarry LP bought a new position in Guardant Health in the 2nd quarter valued at approximately $44,000. Finally, Green Alpha Advisors LLC increased its holdings in shares of Guardant Health by 23.6% in the 3rd quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company’s stock worth $201,000 after purchasing an additional 1,674 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. The Goldman Sachs Group upped their price target on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. UBS Group boosted their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. Craig Hallum raised their target price on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Piper Sandler increased their price target on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $40.60.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the transaction, the director now owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.50% of the company’s stock.

Guardant Health Stock Up 1.5 %

GH stock opened at $35.61 on Friday. The business’s 50-day moving average price is $25.00 and its 200-day moving average price is $27.26. The stock has a market cap of $4.40 billion, a P/E ratio of -8.40 and a beta of 1.11. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $37.04.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.73) earnings per share. On average, equities research analysts forecast that Guardant Health, Inc. will post -3.38 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.